Development pipeline

Phase	Product/ Compound	Indication	Study	Results expected
IV	Bosentan	Combination bosentan & sildenafil in PAH	COMPASS-2	-
IV	Miglustat	Type 1 Gaucher disease patients switched from ERT to miglustat	MAINTENANCE	2010
III	Almorexant	Insomnia	RESTORA	-
III	Clazosentan	Prevention of vasospasm-related morbidity / mortality post aneurysmal subarachnoid hemorrage (SAH)	CONSCIOUS-2 CONSCIOUS-3	H2 2010 2011
III	Macitentan	Pulmonary arterial hypertension	SERAPHIN	H2 2012
III	Selexipag	Pulmonary arterial hypertension	GRIPHON	-
II	CRTH2 antagonist	Asthma	-	-
II	S1P₁ agonist	Multiple Sclerosis	-	-
II	S1P₁ agonist	Plaque psoriasis	-	-
II	Macitentan	Idiopathic pulmonary fibrosis (IPF)	MUSIC	-
I	Antibiotic	Anti-infective	-	-
I	Cardiovascular	Cardiovascular	-	-

Top of page Print pageSend this page to a friendBookmark with del.icio.usBookmark with diggBookmark with MISTER WONG

Lab Technician, Drug Discovery Pharmacology & Preclinical Development

"One day the results of my work could help patients who currently have no treatment of their disease."